Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
<h4>Objective</h4>To assess the efficacy and toxicity of anlotinib for the treatment of refractory advanced non-small-cell lung cancer (NSCLC).<h4>Methods</h4>We systematically searched databases for randomized controlled trials on anlotinib treatment for patients with advanc...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0242982 |